Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma-Reference-Cited by-同舟云学术

Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma

Published:2021-10 Issue: Volume: Page:
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Ahmed Farzana^ORCID,Tseng Hsin-Yi^ORCID,Ahn Antonio^ORCID,Gunatilake Dilini^ORCID,Alavi Sara^ORCID,Eccles Michael^ORCID,Rizos Helen^ORCID,Gallagher Stuart J^ORCID,Tiffen Jessamy C^ORCID,Hersey Peter^ORCID,Emran Abdullah Al^ORCID

Funder

National Health and Medical Research Council

Cancer Council NSW

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference74 articles.

1. Transcriptional reprogramming and constitutive PD-L1 expression in melanoma are associated with dedifferentiation and activation of interferon and tumour necrosis factor signalling pathways;Ahn;Cancers (Basel),2021

2. Targeting autophagy in cancer: recent advances and future directions;Amaravadi;Cancer Discov,2019

3. ATR inhibitors and paclitaxel in melanoma;Ashworth;Clin Cancer Res,2021

4. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways;Bai;Nat Rev Clin Oncol,2019

5. Classical chemotherapy for metastatic melanoma;Becker;Clin Exp Dermatol,2000

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A dendritic cell-recruiting, antimicrobial blood clot hydrogel for melanoma recurrence prevention and infected wound management;Biomaterials;2025-02

2. Antitumor activity of anlotinib in malignant melanoma: modulation of angiogenesis and vasculogenic mimicry;Archives of Dermatological Research;2024-07-03

3. Melanoma biology and treatment: a review of novel regulated cell death-based approaches;Cancer Cell International;2024-02-09

4. Drug Repurposing in Cancer Therapy;Drug Repurposing;2024

5. Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance;Heliyon;2023-07